MDR paper / 2023 ART stop & 350mg LL: Results:

MDR paper / 2023 ART stop & 350mg LL:

Results:
*52 participants were enrolled (25 leronlimab and 27 placebo)
*Leronlimab was generally well tolerated with no drug-related SAEs reported.

Conclusions:
*Leronlimab resulted in significantly reduced plasma HIV-1 within one week after addition to failing ART.
https://journals.lww.com/jaids/abstract/9900/...1.602.aspx

ART stop & 350mg LL to viral breakthrough:
*Overall Number of Baseline Participants: 43
*Adverse events were collected for a total of 18 weeks, from treatment visit 1 (Post Rx) to treatment visit T14 (Week 14) and through the follow up period, every 2 week for total of 4 weeks.

*Serious Adverse Events: 1/43
Nervous system disorders: 1
Transient Ischemic Attack

Principal Investigator:Jacob Lalezari, MD
https://clinicaltrials.gov/study/NCT02175680?...ts&a=9

The internet told me TIA can be related to a blood clot & sign of potential stroke. Usually resolves itsself in minutes to maybe 24 hours. But as usual, no LL post-trial SAE's.

ART stop: 350mg was significant.
MASH: 350mg was significant.
CCL4: 350mg was significant.
MDR: 350mg was significant.